Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
We are committed to making high-value biosimilars affordable for everyone. It’s an unconventional approach to business that defines who we are and what we do.
At Coherus, we hold ourselves to a higher standard. We don’t break the rules—we write our own.
In early 2021, we expanded our mission into immuno-oncology with a collaboration with Shanghai Junshi Biosciences for the development and commercialization of toripalimab, Junshi Biosciences’ novel anti-PD-1 antibody, in the United States and Canada.
We are embarking on a new phase in our evolution, focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Join us, as we seek to break down barriers and make a difference in patients’ lives.
Stock Symbol: CHRS
Stock Exchange: NASDAQ
206 articles with Coherus BioSciences
-
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
11/8/2022
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for its fiscal third quarter ended September 30, 2022 and recent business highlights.
-
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
11/1/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022.
-
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab
10/12/2022
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the publication of toripalimab plus chemotherapy for patients with treatment-naïve advanced non-small cell lung cancer: a multi-center randomized phase 3 trial (CHOICE-01) in the Journal of Clinical Oncology.
-
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
9/19/2022
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) today announced the commercial availability, beginning October 3, 2022, of CIMERLI™ (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all approved indications.
-
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
9/12/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET.
-
Coherus BioSciences Announces New Employment Inducement Grants - Aug 30, 2022
8/30/2022
Coherus BioSciences, Inc., announced that effective August 24, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 234,000 shares of the common stock of the Company to 22 newly hired employees with a per share exercise price of $12.90, the closing trading price on the grant date.
-
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
8/4/2022
Coherus BioSciences, Inc., reported financial results for the quarter ended June 30, 2022 and recent business highlights.
-
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
8/2/2022
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all five indications, meeting the FDA’s rigorous standards to the reference product, including safety, efficacy and quality.
-
Coherus BioSciences Announces New Employment Inducement Grants - Aug 02, 2022
8/2/2022
Coherus BioSciences, Inc., announced that effective August 1, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of the common stock of the Company to two newly hired employees with a per share exercise price of $9.16, the closing trading price on the grant date.
-
The end of July is busy for the FDA, with Coherus, Sanofi, Acadia, Myovant and Pfizer having PDUFA dates filling the calendar. Here’s a look.
-
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
7/28/2022
Coherus BioSciences, Inc., announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022.
-
A cancer drug co-developed by Coherus BioSciences and Junshi Biosciences, toripalimab, is getting another opportunity before the U.S. Food and Drug Administration.
-
Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
7/6/2022
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab.
-
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
7/6/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab.
-
Coherus BioSciences Announces New Employment Inducement Grants - June 22, 2022
6/22/2022
Coherus BioSciences, Inc., announced that effective June 16, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of the common stock of the Company to 16 newly hired employees with a per share exercise price of $5.86, the closing trading price on the grant date.
-
Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors
5/11/2022
Coherus Biosciences, Inc. announced the appointment of cancer immunotherapy leader Jill O’Donnell-Tormey, Ph.D., to its Board of Directors.
-
Coherus BioSciences Management to Present at Upcoming Investor Conferences
5/10/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m. ET UBS Global Healthcare Conference on Tuesday, May 24 at 2:00 p.m. ET.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Coherus BioSciences Reports First Quarter 2022 Results
5/5/2022
Coherus BioSciences, Inc., reported financial results for the quarter ended March 31, 2022 and recent business highlights.
-
Coherus BioSciences Appoints Charlie Newton to Board of Directors
5/5/2022
Coherus BioSciences, Inc. today announced the appointment of former investment banker and renowned biotech strategist Charlie Newton to its Board of Directors.